Trial Profile

A Real-world study on treatment persistence with Golimumab in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in French clinical practice

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golimumab (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
Focus Therapeutic Use
Acronyms GO-PRACTICE

22 Dec 2021 Results of post-hoc analysis (n=478) assessing persistence and safety of golimumab, together with the evolution of disease activity and patient reported outcomes, in adult patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (axSpA) published in the Clinical and Experimental Rheumatology
03 Sep 2020 Results published in the Clinical and Experimental Rheumatology
06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com